Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma

• Status: Terminated
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

It was previously shown that [18F]Fluorodopa (FDOPA) PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory agencies require randomized trials to determine the impact of PET on patient management and outcome. In this study we hypothesize that the addition of FDOPA PET will improve patient outcome by more accurately identifying presence or absence of tumor recurrence than conventional imaging.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Methodist Hospital Research Institute; The Methodist Hospital System
• Collaborator: University of California, Los Angeles
• Treatments: Dihydroxyphenylalanine; Fluorides; Radiopharmaceuticals

Criteria

Inclusion Criteria:

• Suspected first recurrence of a glioblastoma tumor by clinical measures and/or MRI

• Age 18 and older

Exclusion Criteria:

• Breast feeding/ Pregnancy

• Severe psychiatric illness

• Primary diagnosis of a glioblastoma